Obesity and associated metabolic complications, such as non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D), are in constant increase around the world. While most obese patients show several metabolic and biometric abnormalities and comorbidities, a subgroup of patients representing 3% to 57% of obese adults, depending on the diagnosis criteria, remains metabolically healthy. Among many other factors, the gut microbiota is now identified as a determining factor in the pathogenesis of metabolically unhealthy obese (MUHO) individuals and in obesity-related diseases such as endotoxemia, intestinal and systemic inflammation, as well as insulin resistance. Interestingly, recent studies suggest that an optimal healthy-like gut microbiota structure may contribute to the metabolically healthy obese (MHO) phenotype. Here, we describe how dietary medium chain triglycerides (MCT), previously found to promote lipid catabolism, energy expenditure and weight loss, can ameliorate metabolic health via their capacity to improve both intestinal ecosystem and permeability. MCT-enriched diets could therefore be used to manage metabolic diseases through modification of gut microbiota.

One of the major challenges in field research has been the difficulty to adequately measure body composition, such as % body fat and fat-free mass (FFM). Therefore, the purpose of the present study was to investigate the convergent validity of the portable bioelectrical impedance body composition analyzer, the Inbody 230, with dual X-ray absorptiometry (DXA) (General Electric Lunar Prodigy). The study population consisted of 145 men and women (age, 44.6 ± 20 years; BMI, 24.5 ± 3.8 kg·m^–2). We measured body composition (fat mass, % body fat, total FFM, trunk FFM, and appendicular FFM) using DXA and the Inbody 230. Results show strong significant correlations between both methods for fat mass, % body fat, total FFM, and trunk FFM (r = 0.94–0.99). Furthermore, we showed a modest significant correlation between both methods for appendicular FFM (r = 0.63). Finally, as shown by Bland–Altman analysis, no significant biases were observed between Inbody 230 and DXA for fat mass, % body fat, and total FFM. However, trunk and appendicular FFM were shown to have significant biases between the Inbody 230 and DXA. In conclusion, the present study indicated that the portable Inbody 230 may be an acceptable device to measure fat mass, % body fat, and total FFM (except for women) in healthy adults. In addition, there appears to be a systematic bias for the estimation of trunk and appendicular FFM with the Inbody 230 in men and women.